OpenAI acquires AI biotech startup Orchestra Bio to expand Rosalind life sciences platform
OpenAI announced on 2026-10-20 that it acquired Orchestra Bio, a four-year-old AI biotech software startup. Deal terms were not disclosed. Orchestra had reportedly raised about $20 million as of 2025 from backers including Andreessen Horowitz, Atria and 8VC. Orchestra builds AI agents that help biotech companies manage drug discovery operations such as finance tracking and clinical trial scheduling. OpenAI will fold the team and technology into Rosalind, its AI model for life sciences research, and the related Rosalind Workbench tool. Reported Rosalind customers include Moderna and Novo Nordisk. This is business news with no direct threat, vulnerability or incident component.
Linha do tempo
-
OpenAI acquires AI biotech startup Orchestra Bio to expand Rosalind life sciences platform
ler a análise desta fonte ocultar
OpenAI announced on 2026-10-20 that it acquired Orchestra Bio, a four-year-old AI biotech software startup. Deal terms were not disclosed. Orchestra had reportedly raised about $20 million as of 2025 from backers including Andreessen Horowitz, Atria and 8VC. Orchestra builds AI agents that help biotech companies manage drug discovery operations such as finance tracking and clinical trial scheduling. OpenAI will fold the team and technology into Rosalind, its AI model for life sciences research, and the related Rosalind Workbench tool. Reported Rosalind customers include Moderna and Novo Nordisk. This is business news with no direct threat, vulnerability or incident component.